Lymph node metastasis matters.
作者信息
Sugimura Haruhiko, Yoshimura Katsuhiro
机构信息
Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
出版信息
J Thorac Dis. 2019 Mar;11(Suppl 3):S331-S333. doi: 10.21037/jtd.2018.12.127.
Abstract
摘要
相似文献
1
Lymph node metastasis matters.淋巴结转移至关重要。
J Thorac Dis. 2019 Mar;11(Suppl 3):S331-S333. doi: 10.21037/jtd.2018.12.127.
2
[Bladder cancer and the sentinel node concept].[膀胱癌与前哨淋巴结概念]
Aktuelle Urol. 2003 Mar;34(2):115-8. doi: 10.1055/s-2003-38910.
3
Lymph node assessment technique matters in radical cystectomy for bladder cancer.在膀胱癌根治性膀胱切除术时，淋巴结评估技术很重要。
ANZ J Surg. 2023 Mar;93(3):675-679. doi: 10.1111/ans.18292. Epub 2023 Mar 3.
4
[The patterns of cervical lymph node metastasis and the surgical treatment for untreated medullary thyroid carcinoma].[甲状腺髓样癌颈部淋巴结转移模式及未治疗患者的外科治疗]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018 Oct 5;32(19):1504-1506. doi: 10.13201/j.issn.1001-1781.2018.19.016.
5
Clinical Study on Prelaryngeal Lymph Node Metastasis in Papillary Thyroid Carcinoma.甲状腺乳头状癌喉前淋巴结转移的临床研究
Cancer Manag Res. 2020 Feb 21;12:1323-1327. doi: 10.2147/CMAR.S232884. eCollection 2020.
6
The anatomic extent and completeness of pelvic lymphadenectomy is what matters.盆腔淋巴结清扫术的解剖范围和完整性才是关键。
Curr Opin Urol. 2013 Sep;23(5):444-8. doi: 10.1097/MOU.0b013e328363f5f8.
7
[Relationship between tumor size and lymph node metastasis in squamous cell carcinoma and adenocarcinoma of the lung].
Zhongguo Fei Ai Za Zhi. 2006 Jun 20;9(3):267-9. doi: 10.3779/j.issn.1009-3419.2006.03.12.
8
miR-21 Is a Promising Novel Biomarker for Lymph Node Metastasis in Patients with Gastric Cancer.miR-21 是胃癌患者淋巴结转移有潜力的新型生物标志物。
Gastroenterol Res Pract. 2012;2012:640168. doi: 10.1155/2012/640168. Epub 2012 Jun 27.
9
A case of rectal carcinoid, 7 mm in diameter, with skip metastasis to the lateral lymph node.一例直径7毫米的直肠类癌，伴有跳跃性转移至侧方淋巴结。
Mol Clin Oncol. 2016 Apr;4(4):549-552. doi: 10.3892/mco.2016.761. Epub 2016 Feb 2.
10
[Clinical study of cervical lymph node metastasis in maxillary cancer patients].[上颌窦癌患者颈部淋巴结转移的临床研究]
Nihon Jibiinkoka Gakkai Kaiho. 2008 Jun;111(6):486-9. doi: 10.3950/jibiinkoka.111.486.
引用本文的文献
1
Prediction of Lymph-Node Metastasis in Cancers Using Differentially Expressed mRNA and Non-coding RNA Signatures.利用差异表达的mRNA和非编码RNA特征预测癌症中的淋巴结转移
Front Cell Dev Biol. 2021 Feb 11;9:605977. doi: 10.3389/fcell.2021.605977. eCollection 2021.
本文引用的文献
1
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.头颈部鳞状细胞癌免疫检查点抑制剂反应的免疫生物标志物。
Ann Oncol. 2019 Jan 1;30(1):57-67. doi: 10.1093/annonc/mdy507.
2
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.阿替利珠单抗治疗晚期 NSCLC 进展后：来自随机、III 期 OAK 研究的结果。
J Thorac Oncol. 2018 Dec;13(12):1906-1918. doi: 10.1016/j.jtho.2018.08.2027. Epub 2018 Sep 11.
3
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.抑制 IDO 通路治疗癌症：ECHO-301 试验及其他试验的经验教训。
Semin Immunopathol. 2019 Jan;41(1):41-48. doi: 10.1007/s00281-018-0702-0. Epub 2018 Sep 10.
4
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.抗 PD-1/PD-L1 抑制剂或单药化疗治疗的晚期非小细胞肺癌患者的超进展性疾病。
JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.
5
Analysis of Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies.扩增分析：不同恶性肿瘤患者的下一代测序
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00235. Epub 2018 Jul 13.
6
Do immune checkpoint inhibitors need new studies methodology?免疫检查点抑制剂是否需要新的研究方法？
J Thorac Dis. 2018 May;10(Suppl 13):S1564-S1580. doi: 10.21037/jtd.2018.01.131.
7
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.抗 PD-1/PD-L1 治疗复发性和/或转移性头颈部鳞状细胞癌患者中的超进展。
Ann Oncol. 2017 Jul 1;28(7):1605-1611. doi: 10.1093/annonc/mdx178.
8
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.免疫治疗后的超进展者：与加速生长率相关的基因组改变分析。
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250. doi: 10.1158/1078-0432.CCR-16-3133. Epub 2017 Mar 28.
9
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.iRECIST：免疫治疗试验中使用的疗效评估标准指南。
Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2.
10
Genetic biomarkers for PD-1/PD-L1 blockade therapy.用于PD-1/PD-L1阻断疗法的基因生物标志物。
Oncoscience. 2016 Nov 21;3(11-12):311-312. doi: 10.18632/oncoscience.328. eCollection 2016.
Zotero 插件